TRAVATAN Z Drug Patent Profile

Which patents cover Travatan Z, and what generic alternatives are available?

Travatan Z is a drug marketed by Sandoz and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has forty-five patent family members in twenty-three countries.

The generic ingredient in TRAVATAN Z is travoprost. There are fifteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the travoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Travatan Z

A generic version of TRAVATAN Z was approved as travoprost by CHARTWELL RX on March 1^st, 2013.

Summary for TRAVATAN Z

International Patents:	45
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	69
Clinical Trials:	53
Patent Applications:	4,867
Drug Prices:	Drug price information for TRAVATAN Z
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRAVATAN Z
What excipients (inactive ingredients) are in TRAVATAN Z?	TRAVATAN Z excipients list
DailyMed Link:	TRAVATAN Z at DailyMed

See drug prices for TRAVATAN Z

See drug sales revenues for TRAVATAN Z

Recent Clinical Trials for TRAVATAN Z

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Hong Kong	N/A
Laboratorios Sophia S.A de C.V.	Phase 1
Novartis Pharmaceuticals	Phase 4

See all TRAVATAN Z clinical trials

Pharmacology for TRAVATAN Z

Drug Class

Prostaglandin Analog

Paragraph IV (Patent) Challenges for TRAVATAN Z

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRAVATAN Z	Ophthalmic Solution	travoprost	0.004%	021994	1	2009-02-19

US Patents and Regulatory Information for TRAVATAN Z

TRAVATAN Z is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes	8,323,630		Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes	8,268,299		Y
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	AT2	RX	Yes	Yes	8,388,941		Y

Expired US Patents for TRAVATAN Z

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	5,510,383
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	6,849,253
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	5,889,052
Sandoz	TRAVATAN Z	travoprost	SOLUTION/DROPS;OPHTHALMIC	021994-001	Sep 21, 2006	6,503,497

EU/EMA Drug Approvals for TRAVATAN Z

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Novartis Europharm Limited	Izba	travoprost	EMEA/H/C/002738Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma.	Authorised	no	no	no	2014-02-20
Novartis Europharm Limited	Travatan	travoprost	EMEA/H/C/000390Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).	Authorised	no	no	no	2001-11-27

International Patents for TRAVATAN Z

See the table below for patents covering TRAVATAN Z around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	704670
Hong Kong	1010717
Australia	4233693
Spain	2374444
Mexico	2009003042

Supplementary Protection Certificates for TRAVATAN Z

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1920764	CA 2012 00030	Denmark
1920764	PA2012017,C1920764	Lithuania		PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
1920764	SPC/GB12/038	United Kingdom		PRODUCT NAME: TRAVOPROST; REGISTERED: UK EU/1/01/199/001-002 20011129
1920764	12C0045	France		PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
1514548	CA 2014 00038	Denmark		PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127

TRAVATAN Z: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

TRAVATAN Z (travoprost ophthalmic solution) is a prostaglandin analog used to treat open-angle glaucoma and ocular hypertension. Its market performance is influenced by patent exclusivity, generic competition, therapeutic class trends, and regional market penetration.

What is the patent status of TRAVATAN Z?

TRAVATAN Z’s primary patent, U.S. Patent No. 5,152,994, protecting its active ingredient travoprost, expired in June 2015. Subsequent formulation and method-of-use patents also expired. The expiration of key patents allowed for the introduction of generic travoprost products into the market, significantly altering the competitive landscape and pricing dynamics.

How has generic entry impacted TRAVATAN Z sales?

The introduction of generic travoprost has led to a substantial decline in net sales for the branded TRAVATAN Z. Before generic entry, TRAVATAN Z held a significant market share and commanded premium pricing. Post-expiration, price erosion and market share transfer to lower-cost generics have been observed.

• 2014 (Pre-Generic): Alcon (Novartis) reported TRAVATAN Z net sales of approximately $750 million globally.
• 2016 (Post-Generic Entry): Global net sales for TRAVATAN Z declined by over 60% from its peak, with further declines in subsequent years.
• Current Landscape: Multiple generic manufacturers offer travoprost ophthalmic solutions, leading to increased price competition and reduced market share for the branded product.

What is the competitive landscape for travoprost?

TRAVATAN Z competes with other prostaglandin analogs, fixed-combination glaucoma medications, and other drug classes used to lower intraocular pressure (IOP). Key competitors include:

• Latanoprost (Xalatan): The first prostaglandin analog, which also faces generic competition.
• Bimatoprost (Lumigan): Another prostaglandin analog with both branded and generic versions.
• Travoprost/Timolol (DuoTrav): A fixed combination product, now also subject to generic competition for its individual components.
• Other Glaucoma Therapies: Alpha-adrenergic agonists, beta-blockers, carbonic anhydrase inhibitors, and Rho-kinase inhibitors.

The availability of generics for travoprost and its combination products has intensified competition. Prescribing patterns often shift towards cost-effective generics, especially in markets with high healthcare cost-consciousness and robust generic pharmaceutical industries.

What are the key market dynamics in the glaucoma therapeutic class?

The glaucoma market is characterized by:

• Aging Population: Increasing prevalence of glaucoma due to an aging demographic globally.
• Chronic Disease Management: Glaucoma requires lifelong treatment to prevent vision loss, ensuring sustained demand for IOP-lowering medications.
• Technological Advancements: Development of new drug formulations (e.g., sustained-release), drug delivery systems, and combination therapies aiming for improved efficacy, adherence, and reduced side effects.
• Cost Pressures: Healthcare systems and payers increasingly focus on cost-effectiveness, favoring generic medications where available and clinically equivalent.
• Surgical and Laser Interventions: Growing adoption of minimally invasive glaucoma surgery (MIGS) and laser treatments as alternatives or adjuncts to pharmacotherapy, particularly for patients with advanced disease or those not responding adequately to medication.

What is the global market penetration of travoprost?

Travoprost, in both branded and generic forms, has significant global penetration. It is a first-line or second-line treatment option in many treatment algorithms for open-angle glaucoma and ocular hypertension.

• North America: High generic utilization, leading to significant price erosion for branded TRAVATAN Z.
• Europe: Similar trends to North America, with strong regulatory frameworks supporting generic drug availability and cost containment measures.
• Asia-Pacific: Growing market with increasing awareness and diagnosis of glaucoma. Generic travoprost is widely available and prescribed due to cost-effectiveness.
• Latin America: Market dynamics vary by country, but generic penetration is increasing, impacting branded product sales.

What is the financial trajectory and outlook for TRAVATAN Z?

The financial trajectory for branded TRAVATAN Z is one of declining sales and market share due to generic competition. Future revenue generation for the active pharmaceutical ingredient (API) travoprost will primarily come from generic manufacturers.

• Revenue Decline: Post-patent expiration, net sales for branded TRAVATAN Z have seen a sustained decrease year-over-year.
• Market Share Shift: The market share once held by TRAVATAN Z has largely transferred to generic travoprost products.
• Product Lifecycle: TRAVATAN Z has moved into the mature and declining phase of its product lifecycle.
• Strategic Importance: For its originator (Alcon), the financial impact has necessitated a focus on newer, patented products or diversified portfolios to offset the revenue loss from TRAVATAN Z.

What are the key considerations for investors and R&D professionals?

For investors and R&D professionals, the TRAVATAN Z case highlights several critical considerations:

• Patent Cliff Impact: The significant revenue drop post-patent expiry underscores the importance of robust patent strategies and the need for a pipeline of new, differentiated products.
• Generic Competition Strategy: Companies must have a proactive strategy for managing generic entry, including authorized generics or early-stage lifecycle management.
• Therapeutic Area Innovation: The glaucoma market continues to evolve. Innovation in drug delivery (e.g., longer-acting formulations), combination therapies, and non-pharmacological treatments presents ongoing R&D opportunities.
• Market Access and Reimbursement: Understanding payer dynamics and the influence of cost-effectiveness on prescribing patterns is crucial for market success.
• Emerging Markets: While mature markets face intense generic competition, emerging markets may offer longer periods of branded product viability before significant generic erosion.

Key Takeaways

• TRAVATAN Z's primary patent expired in June 2015, leading to the rapid introduction of generic travoprost.
• Generic competition has caused a significant decline in branded TRAVATAN Z sales and market share.
• The glaucoma market is competitive, with travoprost facing alternatives from other prostaglandin analogs and different drug classes.
• Market dynamics are driven by an aging population, chronic disease management needs, cost pressures, and evolving treatment modalities like MIGS.
• Branded TRAVATAN Z has entered the declining phase of its product lifecycle, with future revenue from travoprost residing with generic manufacturers.

FAQs

1. What are the primary indications for travoprost? Travoprost is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

2. What is the typical dosing regimen for TRAVATAN Z? The typical dosage is one drop in the affected eye(s) once daily in the evening.

3. What are the most common side effects associated with travoprost? Common side effects include ocular hyperemia (redness), iris color changes (permanent darkening), eyelash growth, and itching.

4. Can TRAVATAN Z be used concurrently with other glaucoma medications? Yes, TRAVATAN Z can be used as adjunctive therapy with other topical IOP-lowering medications. If more than one topical ophthalmic medication is used, it should be administered at least 5 minutes apart.

5. What is the mechanism of action for travoprost? Travoprost is a prostaglandin analog that reduces intraocular pressure by increasing uveoscleral outflow.

Citations

[1] U.S. Patent No. 5,152,994. (1992). 3-amino-1,2,4-triazole derivative. Retrieved from USPTO Patent Database. [2] Novartis AG. (2015). Novartis Annual Report 2015. [3] Alcon (a Novartis company). (2014). Alcon Annual Report 2014.